Ophthalmic Drugs Market Report 2026

The ophthalmic drugs market size has grown strongly in recent years. It will grow from $42.25 billion in 2025 to $45.24 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing aging population, rising incidence of glaucoma and cataract, growth in ophthalmology clinics, improved access to prescription eye medicines, expansion of hospital pharmacy networks.

The ophthalmic drugs market size is expected to see strong growth in the next few years. It will grow to $61.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancement in sustained-release ocular drug delivery, increasing awareness of eye health, growth in retinal disorder treatments, rising healthcare expenditure in emerging economies, expanding otc ophthalmic product adoption. Major trends in the forecast period include rising prevalence of chronic eye disorders, growing demand for dry eye therapies, increased adoption of combination ophthalmic drugs, shift toward preservative-free formulations, expansion of online pharmacies for eye medications.

The rising prevalence of ophthalmic disorders is anticipated to drive the growth of the ophthalmic drugs market in the coming years. Ophthalmic disorders include diseases or conditions that affect the eyes or related structures, leading to vision impairment and other eye-related complications. Ophthalmic drugs are pharmaceutical products used to treat conditions affecting the eyes or vision; therefore, an increase in the prevalence of ophthalmic disorders directly raises demand for ophthalmic medications. For instance, in August 2023, according to the World Health Organization (WHO), a Switzerland-based United Nations organization, at least 2.2 billion people worldwide were living with near or distance vision impairment in 2023, with more than 1 billion cases being preventable or untreated. Refractive errors and cataracts were identified as the leading causes, with intervention coverage limited to just 36% and 17%, respectively. Thus, the growing prevalence of ophthalmic disorders is contributing to the expansion of the ophthalmic drugs market.

Key companies operating in the ophthalmic drugs market are concentrating on the development of preservative-free formulations, such as preservative-free latanoprost, to offer effective treatment options. Preservative-free latanoprost is a formulation of latanoprost used in the management of conditions such as glaucoma. For example, in September 2023, Thea Pharma, a US-based pharmaceutical company focused on commercializing eye care products, launched Iyuzeh (latanoprost ophthalmic solution) 0.005%, the first preservative-free latanoprost approved in the United States for the treatment of primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Iyuzeh, which received FDA approval in December 2022, provides an effective treatment option for more than 60 million people worldwide affected by glaucoma.

In November 2025, Harrow Inc., a US-based provider of ophthalmic disease management solutions, acquired Melt Pharmaceuticals for an undisclosed amount. Through this acquisition, Harrow seeks to broaden its ophthalmic drug portfolio and enhance its capabilities in procedural sedation by incorporating Melt’s non-opioid, non-intravenous sublingual sedation therapies into its wider ophthalmic and outpatient care offerings. Melt Pharmaceuticals is a US-based clinical-stage company developing non-opioid, non-IV oral dissolving tablet sedation therapies for medical procedures in ophthalmology and other outpatient settings.

Major companies operating in the ophthalmic drugs market are AbbVie Inc., Alcon Inc., Bausch & Lomb Incorporated, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Nicox S.A., Johnson & Johnson, Otsuka Pharmaceutical Co. Ltd., Viatris Inc., Akorn Incorporated, GlaxoSmithKline plc, Bayer AG, Senju Pharmaceutical Co. Ltd., Aerie Pharmaceuticals Inc., Kala Pharmaceuticals Inc., Aurobindo Pharma Ltd., Eyevance Pharmaceuticals, Acucela Inc., Dompe Farmaceutici S.p.A., Laboratoires Théa.

North America was the largest region in the ophthalmic drugs market in 2025. The regions covered in the ophthalmic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ophthalmic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the ophthalmic drugs market by increasing the cost of imported active pharmaceutical ingredients, packaging materials, and specialized drug delivery components, leading to higher production and pricing pressures. Prescription drug segments such as antiglaucoma agents and retinal disorder treatments, along with regions dependent on cross-border pharmaceutical supply chains including asia-pacific and europe, are most affected. However, tariffs have also encouraged local manufacturing, regional sourcing of raw materials, and investments in domestic pharmaceutical production, supporting long-term supply chain resilience and market stability.

The ophthalmic drugs market research report is one of a series of new reports that provides ophthalmic drugs market statistics, including ophthalmic drugs industry global market size, regional shares, competitors with a ophthalmic drugs market share, detailed ophthalmic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmic drugs industry. This ophthalmic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ophthalmic drugs are a category of pharmaceutical medicines used to treat conditions affecting the eyes or vision. These medications are commonly prescribed for managing eye infections and other ocular disorders.

The primary types of ophthalmic drugs include prescription medications and over-the-counter drugs. Prescription ophthalmic drugs are those that can be obtained only with a prescription from a licensed physician or medical practitioner. The different classes include anti-allergy, anti-inflammatory, anti-glaucoma, and other drug classes used to treat conditions such as dry eye, eye allergies, glaucoma, eye infections, retinal disorders, uveitis, and other eye diseases. These drugs are available in various dosage forms, including liquid ophthalmic formulations, solid ophthalmic forms, semisolid ophthalmic forms, and multicompartment drug delivery systems. They are distributed through multiple channels, including hospital pharmacies, drug stores, and online pharmacies.

The ophthalmic drugs market consists of ophthalmic sales of anti-angiogenic drugs, anti-vascular endothelial growth factor drugs, anti-uveitis drugs, and prostaglandin analogs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.